Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 2018Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
ORIGINAL ARTICLE

Public disclosure of clinical trial results at Clinical Trial Registry of India- need for transparency in research!


 Department of Clinical Pharmacology, T. N. Medical College and BYL Nair Ch. Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Renuka Munshi,
Department of Clinical Pharmacology, T. N. Medical College and BYL Nair Ch. Hospital, Mumbai Central, Mumbai - 400 008, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/picr.picr_39_22

Introduction: Since June 15, 2009, clinical trial registration in the Clinical Trial Registry-India (CTRI) has been made mandatory by the Drugs Controller General of India to improve transparency, accountability, conform to accepted ethical standards and reporting of all relevant results of registered trials. In this study, we planned to evaluate the compliance of Indian and global sponsors with clinical trials conducted in India in terms of reporting of clinical trial results at the CTRI. Methods: We included trials registered in the CTRI between January 2018 and January 2020. The CTRI and ClinicalTrials.gov registry was thoroughly searched for all completed interventional studies. A year-wise comparative analysis was performed to evaluate the number of clinical trials reporting results in both the registry. Results: The reporting of completed interventional clinical trial results was 25/112 (22.32%) in year 2018, y, 8/105 (7.6%) in year 2019 and 17/140 (12.14%) in year 2020. There was significantly less reporting of results of Pharmaceutical company sponsored Interventional Studies-Indian at CTRI when compared with ClinicalTrials.gov registry for the year 2019 (odds ratio [OR]-0.17 (95% confidence interval [CI]: 0.08–0.36) and P < 0.0001) and year 2020 (OR-0.45 [95% CI: 0.24–0.82] and P < 0.01). The difference in results reported at CTRI was significantly low for Pharmaceutical company sponsored Interventional Studies-Global only for year 2019 (OR-0.09 [95% CI: 0.005–1.45] and P = 0.04) compared with ClinicalTrials.gov. Conclusion: There is a need to develop the culture of reporting clinical trial results in CTRI to strengthen the transparency in the research for overall benefit of public, health care professionals, and research community.
    
 

  Search Pubmed for
 
    -  Munshi R
    -  Pilliwar C
    -  Maurya MR
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed272    
    PDF Downloaded8    

Recommend this journal